Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by RenovoRx, Inc.

< Previous 1 2 Next >
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Proposed Public Offering
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx CEO Issues Update Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces $11.1 Million at Market Private Placement
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Highlights Key Leadership Promotions
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx CEO Issues Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Closes $6.1 Million Private Placement
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.